Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 28;16(36):4515-8.
doi: 10.3748/wjg.v16.i36.4515.

Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease

Affiliations

Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease

Kenji Tamura et al. World J Gastroenterol. .

Abstract

The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not require any treatment, unless they are indistinguishable from other cystic tumor types with malignant potential. Because pancreatic NET in VHL disease are non-functioning and have malignant potential, it is of clinical importance to find and diagnose these as early as possible. It will be recommended that comprehensive surveillance using dynamic computed tomography for abdominal manifestations, including pancreatic NET, should start from the age of 15 years in VHL patients. Unlike sporadic non-functioning NET without VHL disease, in which surgical resection is generally recommended, VHL patients at lower metastatic risk of pancreatic NET should be spared the risks of operative resection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Abdominal computed tomography shows several cystic lesions in the pancreas (32-year-old female).
Figure 2
Figure 2
Contrast-enhanced abdominal computed tomography reveals several pancreatic mass lesions that are strongly enhanced (33-year-old female)[14].

References

    1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067. - PubMed
    1. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443–447. - PMC - PubMed
    1. Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990;155:501–505. - PubMed
    1. Eras M, Yenigun M, Acar C, Kumbasar B, Sar F, Bilge T. Pancreatic involvement in Von Hippel-Lindau disease. Indian J Cancer. 2004;41:159–161. - PubMed
    1. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O'Toole D, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119:1087–1095. - PubMed

Publication types